Previously reported ()-5'--aminopropyl-2'-arabinofluoro-thymidine () and newly synthesized ()-5'--aminopropyl-2'-arabinofluoro-5-methyl-cytidine () analogs were incorporated into a series of antisense gapmers containing multiple phosphorothioate (PS) linkages and locked nucleic acids (LNAs) in their wing regions. The functional properties of the gapmers were further evaluated in vitro. Compared with the positive control, for the LNA-wing full PS gapmer without modification, it was revealed that each gapmer could have a high affinity and be thermally stable under biological conditions. Although the cleavage pattern was obviously changed; gapmers with modification could still efficiently activate RNase H1. In addition, incorporating one modification into the two phosphodiester linkages could reverse the destabilization in enzymatic hydrolysis caused by fewer PS linkages. In vitro cellular experiments were also performed, and the Lipofectamine 2000 (LFA)+ group showed relatively higher antisense activity than the LFA-free group. KN5ara-10, which contains fewer PS linkages, showed similar or slightly better antisense activity than the corresponding full PS-modified KN5ara-3. Hence, KN5ara-10 may be the most promising candidate for -targeted cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654562 | PMC |
| http://dx.doi.org/10.3390/molecules27217384 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney.
Mol Ther Nucleic Acids
March 2025
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nucleic acid medicine encompassing antisense oligonucleotides (ASOs) has garnered interest as a potential avenue for next-generation therapeutics. However, their therapeutic application has been constrained by challenges such as instability, off-target effects, delivery issues, and immunogenic responses. Furthermore, their practical utility in treating kidney diseases remains unrealized.
View Article and Find Full Text PDFDiscovery and characterization of stereodefined PMO-gapmers targeting tau.
Mol Ther Nucleic Acids
March 2025
Eisai Inc., 35 Cambridgepark Drive, Cambridge, MA 02140, USA.
Antisense oligonucleotides (ASOs) are an important class of therapeutics to treat genetic diseases, and expansion of this modality to neurodegenerative disorders has been an active area of research. To realize chronic administration of ASO therapeutics to treat neurodegenerative diseases, new chemical modifications that improve activity and safety profiles are still needed. Furthermore, it is highly desirable to develop a single stereopure ASO with a defined activity and safety profile to avoid any efficacy and safety concerns due to the batch-to-batch variation in the composition of diastereomers.
View Article and Find Full Text PDFMultispanning membrane protein SIDT2 increases knockdown activity of gapmer antisense oligonucleotides.
Sci Rep
January 2025
Osaka Medical and Pharmaceutical University, 4-20-1, Nasahara, Takatsuki, 569-1094, Osaka, Japan.
Recent advances in the clinical development of oligonucleotide therapeutics, such as antisense oligonucleotides (ASOs) and small interfering RNAs, have attracted attention as promising therapeutic modalities for genetic and intractable diseases. These oligonucleotide therapeutics exert their efficacy by binding to target RNAs present within cells; however, the mechanisms underlying their cellular uptake, especially their passage through membranes, remain largely unclear. In the nematode, Caenorhabditis elegans, the multi-pass transmembrane protein, SID-1, is involved in the cellular uptake of double-stranded RNAs.
View Article and Find Full Text PDFSynthesis of LNA gapmers that replace a phosphorothioate linkage with a sulfonamide in the gap region, and their ability to form duplexes with complementary RNA targets.
Org Biomol Chem
January 2025
Department of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta-cho Midori-ku, 226-8501, Yokohama, Japan.
Antisense oligodeoxynucleotides can bind to target RNAs and cleave them using RNase H. Despite the high activity of antisense oligodeoxynucleotides modified with locked nucleic acids (LNA) at several bases at both the 5' and 3' ends (LNA gapmer), toxicity has been reported, necessitating additional backbone modifications to reduce toxicity. In this study, we introduced a sulfonamide linkage into the LNA gapmer to elucidate its fundamental properties such as hybridization, base recognition, and induction of RNase H activity.
View Article and Find Full Text PDFQuantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system.
Mol Ther
December 2024
RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA 01605 USA; Department of Biochemistry and Molecular Biotechnology, UMass Chan Medical School, Worcester, MA 01605, USA. Electronic address:
Antisense oligonucleotides (ASOs) are emerging as a promising class of therapeutics for neurological diseases. When injected directly into cerebrospinal fluid, ASOs distribute broadly across brain regions and exert long-lasting therapeutic effects. However, many phosphorothioate (PS)-modified gapmer ASOs show transient motor phenotypes when injected into the cerebrospinal fluid, ranging from reduced motor activity to ataxia or acute seizure-like phenotypes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!